Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-17T20:25:46.861Z Has data issue: false hasContentIssue false

Measles vaccine: a 27–year follow–up

Published online by Cambridge University Press:  15 May 2009

M. E. B. Ramsay
Affiliation:
Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ
D. Moffatt
Affiliation:
Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ
M. O'connor
Affiliation:
Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

In 1964, the Medical Research Council undertook a trial of measles vaccine in over 36000 United Kingdom children; 9577 of whom received live vaccine, 10625 received inactivated followed by live vaccine, and 16328 acted as unvaccinated controls. Participants in this study have been followed to determine the long term protection from measles vaccine and follow-up data were available on 4194, 4638 and 274 respectively. During the 5–year period 1986–90, the protective efficacy of live measles vaccine has remained high at 87%, but the 95% confidence interval was wide ( –43 to 99%) due to the small numbers of cases. Between 1976 and 1990, however, the overall efficacy of the live vaccine was 92% (95% confidence interval 86 to 95%) and there was no evidence of a decline in efficacy (P = 0.13) over the 15–year period. This study suggests that the protection from live measles vaccine persists for up to 27 years after vaccination, and that no change in the current United Kingdom measles immunization policy should be made on the grounds of waning immunity.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 1994